Newsfeeds - Spark Newswire

2 minute read

News

VYNE Therapeutics Announces BET Inhibitor, VYN201, Demonstrates Improvement In Reducing Fibrotic Tissue Mass And Overall Skin Repair Outcomes In Preclinical Study

Today, 11:59 AM

VYNE Therapeutics Inc. (NASDAQ:VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”)

VYNE

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 11:59 AM

ARTL

1 minute read

VYNE Therapeutics’ BET Inhibitor Shows Encouraging Preclinical Action

By Vandana Singh

Today, 11:59 AM

VYNE Therapeutics Inc (NASDAQ:VYNE) announced preclinical data for VYN201, its pan-bromodomain and extra-terminal (BET) inhibitor. The data showed that VYN201 significantly…

VYNE

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 11:59 AM

AWH

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 11:59 AM

AVAH

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 11:59 AM

ACER

5 minute read

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal

By Shanthi Rexaline

Today, 11:59 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)

ABEO

6 minute read

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

By Shanthi Rexaline

Today, 11:59 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)

ADTX

2 minute read

Earnings

Looking Into VYNE Therapeutics’s Return On Capital Employed

By Benzinga Insights

Today, 11:59 AM

According to data from Benzinga Pro, during Q2, VYNE Therapeutics's (NASDAQ:VYNE) reported sales totaled $4.26 million. Despite a 3.35% increase in earnings, the company posted a loss of $18.78 million.

VYNE

5 minute read

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO

By Shanthi Rexaline

Today, 11:59 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)

ADMA